HP
VYGR icon

Harbourvest Partners’s Voyager Therapeutics VYGR Stock Holding History

Harbourvest Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-61,776
Closed -$476K – 63
2023
Q1 		$476K Buy
+61,776
New +$491K 0.16% 46
2019
Q1 		– Sell
-72,726
Closed -$684K – 37
2018
Q4 		$684K Hold
72,726
– – 0.32% 23
2018
Q3 		$1.38M Buy
+72,726
New +$1.4M 1.24% 13
2017
Q3 		– Sell
-44,606
Closed -$400K – 27
2017
Q2 		$400K Buy
+44,606
New +$449K 0.17% 21
2017
Q1 		– Sell
-36,362
Closed -$463K – 21
2016
Q4 		$463K Buy
+36,362
New +$467K 0.28% 13

Other funds holding VYGR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Harbourvest Partners's VYGR Position: Q2 2023 in Review

Harbourvest Partners sold out of Voyager Therapeutics (VYGR) in Q2 2023, closing a stake of 61,776 shares — an estimated $476K sold.

Harbourvest Partners first reported a position in VYGR in Q4 2016 and held it in 5 quarters. The position peaked at $1.38M in Q3 2018. 106 funds tracked by Wall St. Rank hold VYGR as of Q2 2023.

  • Harbourvest Partners reported no remaining Voyager Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Harbourvest Partners sold 61,776 Voyager Therapeutics shares in Q2 2023, an estimated $476K.
  • Harbourvest Partners first reported a position in Voyager Therapeutics in Q4 2016 and held it in 5 quarters.
  • Harbourvest Partners's Voyager Therapeutics position peaked at $1.38M in Q3 2018.
  • 106 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2023.

Based on Harbourvest Partners's 13F filing for Q2 2023, filed 14 Aug 2023.